# chronic obstructive pulmonary disease (COPD) - gemini-3.6-flash

- Benchmark system: raw
- Repeat: 6
- Task type: DISEASE-STATE
- Tissue / sample source: lung tissue
- Comparison or endpoint: COPD versus normal control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: 75cb1462dc859d10e673df1637d9bfb35fbfd41f53bda923e17881eee80cc2ef
- Response HTTP status: 200
- Prompt tokens: 5557
- Completion tokens: 12523
- Reasoning tokens: 
- Total tokens: 18080
- API requests reported: 
- Elapsed seconds: 26.147
- Final benchmark system: raw; file rank 4/5; original repeat 6; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

The input transcriptomic dataset compares lung tissue from patients with chronic obstructive pulmonary disease (COPD) against normal controls. Overall, the differential expression pattern reflects a multi-faceted tissue response characterized by **structural and epithelial barrier integrity alterations**, **activation of mucosal innate and vascular-hemostatic pathways**, and **pervasive non-coding RNA-driven transcriptional/epigenetic regulation**.

Rather than isolated single-gene alterations, the data point toward coordinated microenvironmental shifts:
*   **Structural and Extracellular Matrix (ECM) Remodeling:** Upregulation of cytoskeletal cross-linkers (`MACF1`), tight junction components (`CLDN16`), and key regulators of fibrotic signaling (`GREM1`, `POMK`) indicates ongoing structural reorganization, epithelial seal modulation, and altered cell-matrix interactions typical of chronic airway injury and remodeling in COPD.
*   **Mucosal Defense and Vascular/Hemostatic Signals:** Upregulation of antimicrobial peptides (`DEFB1`), acute-phase/coagulation factors (`FGG`), immune receptor ligands (`NCR3LG1`), and immunoglobulin variable chains (`IGKV1-8`) suggests active mucosal innate defense, localized plasma cell infiltration, and increased vascular permeability/hemostatic activation in diseased lung parenchyma.
*   **Epigenetic and Non-Coding Regulatory Reprogramming:** A dominant features of this dataset is the prominent representation of non-coding RNAs—specifically antisense lncRNAs (`SNX29-AS3`, `CELF2-AS1`, `LRP1-AS`, `TGFB2-AS1`, `INHBA-AS1`, `SERPINB9-AS1`), microRNAs (`MIR132`, `MIR3665`), and transcriptional pause regulators (`RN7SK`)—alongside master transcription factors such as `ETV3L` and `ZBED6`. This points to extensive post-transcriptional and epigenetic feedback mechanisms regulating local cell fate and stress responses.
*   **Translational and Proteostatic Suppression:** Downregulation of `NACA2` (a chaperone for nascent polypeptide chains on ribosomes) together with reduced expression of translational and mitochondrial-associated pseudogenes/transcripts (`UQCRBP1`, `RPL23AP32`) suggests a suppressed or impaired baseline translation/protein-folding machinery under chronic metabolic or oxidative stress.

---

### 2. Core Biological Programs

```
COPD Lung Transcriptomic Landscape
 ├── 1. Airway Epithelial Barrier Integrity & Structural Remodeling (UP: MACF1, CLDN16, GREM1, POMK)
 ├── 2. Non-Coding RNA-Mediated Transcriptional & Epigenetic Control (UP: RN7SK, TGFB2-AS1, INHBA-AS1, MIR132)
 ├── 3. Mucosal Innate Defense & Vascular-Hemostatic Response (UP: DEFB1, FGG, NCR3LG1, IGKV1-8)
 └── 4. Proteostatic Machinery & Translation Regulation (DOWN: NACA2, UQCRBP1, RPL23AP32)
```

#### Program 1: Airway Epithelial Barrier Integrity and Structural Remodeling
*   **Direction:** Upregulated
*   **Major Supporting Genes:** `MACF1` ($\text{log}_2\text{FC} = 1.56$, $\text{FDR} = 4.02 \times 10^{-7}$), `CLDN16` ($\text{log}_2\text{FC} = 1.70$, $\text{FDR} = 3.87 \times 10^{-4}$), `GREM1` ($\text{log}_2\text{FC} = 1.65$, $\text{FDR} = 7.16 \times 10^{-3}$), `POMK` ($\text{log}_2\text{FC} = 1.06$, $\text{FDR} = 1.23 \times 10^{-3}$).
*   **Standardized Pathway:** GO:0045216 (Cell-cell junction organization) / Reactome: R-HSA-1474290 (Collagen formation and ECM organization).
*   **Biological Explanation:** `MACF1` bridges actin filaments and microtubules to maintain cellular architecture, while `CLDN16` forms tight junctions regulating paracellular permeability. Upregulation of these structural components, combined with `GREM1` (a secreted BMP antagonist that unleashes pro-fibrotic TGF-$\beta$ signaling) and `POMK` (essential for dystroglycan glycosylation and ECM linkage), reflects compensatory or pathological remodeling of the airway epithelial-mesenchymal trophic unit in response to chronic injury.
*   **Evidence Strength & Limitations:** High statistical significance for individual genes (`MACF1`, `CLDN16`). However, `CLDN16` expression is canonically restricted to renal tissue; its presence in bulk lung transcriptomics may reflect localized epithelial transdifferentiation, aberrant expression, or cell-type composition shifts.

#### Program 2: Non-Coding RNA-Mediated Transcriptional and Epigenetic Control
*   **Direction:** Upregulated (Dominant LncRNA / miRNA / snRNA signature)
*   **Major Supporting Genes:** `RN7SK` ($\text{log}_2\text{FC} = 1.77$, $\text{FDR} = 3.13 \times 10^{-6}$), `SNX29-AS3` ($\text{log}_2\text{FC} = 1.68$, $\text{FDR} = 1.01 \times 10^{-9}$), `CELF2-AS1` ($\text{log}_2\text{FC} = 2.06$, $\text{FDR} = 1.08 \times 10^{-8}$), `TGFB2-AS1` ($\text{log}_2\text{FC} = 1.04$, $\text{FDR} = 7.37 \times 10^{-3}$), `INHBA-AS1` ($\text{log}_2\text{FC} = 1.19$, $\text{FDR} = 1.36 \times 10^{-2}$), `MIR132` ($\text{log}_2\text{FC} = 1.65$, $\text{FDR} = 2.37 \times 10^{-4}$).
*   **Standardized Pathway:** Reactome: R-HSA-212165 (Epigenetic regulation of gene expression) / GO:0035194 (RNA-mediated gene silencing).
*   **Biological Explanation:** `RN7SK` non-coding RNA sequesters P-TEFb (CDK9/Cyclin T1) to control global RNA Polymerase II transcriptional pausing. Concurrently, antisense transcripts corresponding to major growth factor loci (`TGFB2-AS1`, `INHBA-AS1`, `LRP1-AS`) suggest active cis/trans regulatory feedback loops modulating TGF-$\beta$/Activin signaling pathways in diseased tissue.
*   **Evidence Strength & Limitations:** Strong statistical confidence across dozens of non-coding features. The primary limitation is functional annotation: many lncRNAs are classified based on sequence proximity to parent coding genes rather than direct functional characterization in lung tissue.

#### Program 3: Mucosal Innate Defense and Vascular-Hemostatic Response
*   **Direction:** Upregulated
*   **Major Supporting Genes:** `DEFB1` ($\text{log}_2\text{FC} = 1.40$, $\text{FDR} = 7.37 \times 10^{-3}$), `FGG` ($\text{log}_2\text{FC} = 1.76$, $\text{FDR} = 5.31 \times 10^{-3}$), `NCR3LG1` ($\text{log}_2\text{FC} = 0.95$, $\text{FDR} = 4.48 \times 10^{-3}$), `IGKV1-8` ($\text{log}_2\text{FC} = 1.84$, $\text{FDR} = 8.59 \times 10^{-4}$), `CRACR2A` ($\text{log}_2\text{FC} = 1.03$, $\text{FDR} = 3.57 \times 10^{-4}$).
*   **Standardized Pathway:** KEGG: hsa04610 (Complement and coagulation cascades) / Reactome: R-HSA-168249 (Innate Immune System).
*   **Biological Explanation:** Airway epithelial cells upregulate `DEFB1` (Beta-defensin 1) as a antimicrobial barrier mechanism against chronic microbial colonization. Elevated `FGG` (Fibrinogen gamma chain) indicates microvascular permeability and local fibrin deposition, while `NCR3LG1` (B7-H6, an NK cell activation ligand) and `IGKV1-8` signal recruitment and activation of innate immune cells and local plasma cells.
*   **Evidence Strength & Limitations:** Supported by well-annotated canonical genes. However, in bulk tissue transcriptomics, immune markers (`IGKV1-8`, `FGG`) cannot be definitively separated into cell-intrinsic gene induction versus increased immune cell infiltration or vascular exudate.

#### Program 4: Proteostatic Machinery and Translation Regulation
*   **Direction:** Downregulated
*   **Major Supporting Genes:** `NACA2` ($\text{log}_2\text{FC} = -1.15$, $\text{FDR} = 4.02 \times 10^{-4}$), `UQCRBP1` ($\text{log}_2\text{FC} = -1.20$, $\text{FDR} = 3.13 \times 10^{-6}$), `RPL23AP32` ($\text{log}_2\text{FC} = -1.66$, $\text{FDR} = 1.36 \times 10^{-4}$), `SPSB3` ($\text{log}_2\text{FC} = -0.82$, $\text{FDR} = 9.52 \times 10^{-3}$).
*   **Standardized Pathway:** Reactome: R-HSA-72764 (Translation) / GO:0006412 (Protein translation).
*   **Biological Explanation:** `NACA2` prevents inappropriate targeting and degradation of nascent polypeptide chains emerging from the ribosome. Its downregulation, combined with reductions in ribosomal/mitochondrial pseudogene-related transcripts (`RPL23AP32`, `UQCRBP1`) and ubiquitin ligase adaptors (`SPSB3`), indicates a state of proteostatic stress or suppressed general translation in affected tissue cells.
*   **Evidence Strength & Limitations:** Moderate statistical evidence; however, several downregulated targets are pseudogenes or non-coding elements, introducing potential alignment ambiguity in bulk RNA-seq processing.

---

### 3. Key Genes and Interaction Modules

| Candidate Gene / Module | Direction in Dataset | Biological Program | Proposed Interaction Type | Mechanism & Relationship |
| :--- | :--- | :--- | :--- | :--- |
| **`ETV3L`** | Upregulated ($\text{log}_2\text{FC} = 1.47, \text{FDR} = 2.75 \times 10^{-11}$) | Epigenetic / Transcriptional Control | **Regulatory interaction** | ETS-domain transcription factor; binds promoter elements to repress or activate transcriptional programs involved in cell differentiation and inflammation. |
| **`MACF1`** | Upregulated ($\text{log}_2\text{FC} = 1.56, \text{FDR} = 4.02 \times 10^{-7}$) | Epithelial Barrier & Cytoskeleton | **Direct physical interaction** | Direct physical interaction with F-actin and microtubules; acts as a cytolinker maintaining cellular mechanical stability and cell-matrix junctions. |
| **`RN7SK`** | Upregulated ($\text{log}_2\text{FC} = 1.77, \text{FDR} = 3.13 \times 10^{-6}$) | Epigenetic / Transcriptional Control | **Direct physical interaction** | Direct physical binding to P-TEFb (CDK9/Cyclin T1) and HEXIM1, inhibiting P-TEFb-mediated RNA Polymerase II elongation. |
| **`GREM1`** | Upregulated ($\text{log}_2\text{FC} = 1.65, \text{FDR} = 7.16 \times 10^{-3}$) | Epithelial Remodeling & ECM | **Direct physical / Regulatory interaction** | Direct extracellular binding to BMP-2/4/7 (BMP antagonism), indirectly promoting TGF-$\beta$-driven extracellular matrix synthesis and fibrotic remodeling. |
| **`DEFB1`** | Upregulated ($\text{log}_2\text{FC} = 1.40, \text{FDR} = 7.37 \times 10^{-3}$) | Mucosal Innate Defense | **Pathway co-membership** | Secreted antimicrobial peptide operating in the airway surface liquid; part of the mucosal innate immune defense pathway. |
| **`FGG`** | Upregulated ($\text{log}_2\text{FC} = 1.76, \text{FDR} = 5.31 \times 10^{-3}$) | Vascular-Hemostatic Response | **Direct physical interaction** | Assembles physically with FGA and FGB chains to form functional circulating fibrinogen, contributing to local matrix deposition upon vascular leak. |
| **`NACA2`** | Downregulated ($\text{log}_2\text{FC} = -1.15, \text{FDR} = 4.02 \times 10^{-4}$) | Proteostasis & Translation | **Direct physical interaction** | Direct physical binding to ribosome-bound nascent polypeptide chains, protecting them from unintended cytosolic degradation. |
| **`TGFB2-AS1` / `INHBA-AS1` Module** | Upregulated (`TGFB2-AS1`: 1.04; `INHBA-AS1`: 1.19) | Epigenetic Control of Fibrotic Signaling | **Regulatory interaction / Co-expression** | Antisense lncRNAs transcribed from genomic loci encoding TGF-$\beta$ superfamily members (`TGFB2`, `INHBA`), regulating parental mRNA stability or epigenetic landscape in cis/trans. |
| **`NCR3LG1`** | Upregulated ($\text{log}_2\text{FC} = 0.95, \text{FDR} = 4.48 \times 10^{-3}$) | Innate Immune Surveillance | **Direct physical interaction** | Direct physical binding to the activating receptor NKp30 (NCR3) expressed on NK cells and subset of T cells. |
| **`CLDN16`** | Upregulated ($\text{log}_2\text{FC} = 1.70, \text{FDR} = 3.87 \times 10^{-4}$) | Epithelial Barrier Integrity | **Direct physical interaction** | Direct physical assembly into tight junction strands with claudins and ZO-1 to modulate epithelial intercellular permeability. |

---

### 4. Validation Priorities

```
Validation Roadmap
 ├── 1. GREM1 in BMP/TGF-β Fibrotic Remodeling (Mechanistic / Target) [Supported Hypothesis]
 ├── 2. MACF1 Cytoskeletal Integration in Airway Stress (Mechanistic Hypothesis) [Supported Hypothesis]
 ├── 3. Deconvolution of Immune vs Parenchymal Signals (Confounding Check) [Exploratory Hypothesis]
 ├── 4. Functional Impact of TGFB2-AS1 & INHBA-AS1 (Interaction Hypothesis) [Exploratory Hypothesis]
 └── 5. ETV3L Target Profiling in Lung Epithelium (Biomarker / Mechanistic) [Exploratory Hypothesis]
```

#### Priority 1: Functional Role of GREM1 in Airway Fibrotic Remodeling
*   **Classification:** Mechanistic hypothesis / Therapeutic target
*   **Why Prioritize:** `GREM1` is a potent endogenous antagonist of BMP signaling known to promote uninhibited TGF-$\beta$ driving extracellular matrix deposition and airway remodeling.
*   **Current Dataset Evidence:** Upregulated ($\text{log}_2\text{FC} = 1.65, \text{FDR} = 7.16 \times 10^{-3}$), alongside elevated antisense RNAs for TGF-$\beta$ family ligands (`TGFB2-AS1`, `INHBA-AS1`).
*   **External Evidence:** GREM1 is implicated in pulmonary fibrosis and vascular remodeling; BMP inhibition exacerbates parenchymal remodeling in animal models of lung disease.
*   **Next Step for Validation:** Recombinant GREM1 treatment or siRNA knockdown in primary human lung fibroblasts, followed by Western blot for Phospho-SMAD1/5/8 vs. Phospho-SMAD2/3 and collagen gel contraction assays.
*   **Conclusion Status:** **Supported hypothesis**

#### Priority 2: MACF1-Mediated Airway Epithelial Barrier Stabilization
*   **Classification:** Mechanistic hypothesis
*   **Why Prioritize:** `MACF1` is among the most statistically significant protein-coding genes in the dataset ($\text{FDR} = 4.02 \times 10^{-7}$), critical for integrating actin-microtubule dynamics under mechanical stress.
*   **Current Dataset Evidence:** Upregulated ($\text{log}_2\text{FC} = 1.56$), co-occurring with tight junction protein upregulation (`CLDN16`).
*   **External Evidence:** MACF1 is necessary for wound healing and cell migration in respiratory and intestinal epithelia.
*   **Next Step for Validation:** Air-Liquid Interface (ALI) cultures of primary human bronchial epithelial cells (HBECs) subjected to cigarette smoke extract (CSE); measure transepithelial electrical resistance (TEER) and MACF1 protein localization via immunofluorescence.
*   **Conclusion Status:** **Supported hypothesis**

#### Priority 3: Cell-Composition Deconvolution of Hemostatic and Immune Transcripts
*   **Classification:** Confounding or composition check
*   **Why Prioritize:** Signals like `IGKV1-8` (immunoglobulin) and `FGG` (fibrinogen) could represent parenchymal cell gene induction OR altered tissue cell composition (increased plasma cell infiltration / vascular plasma exudate).
*   **Current Dataset Evidence:** Strong upregulation of `IGKV1-8` ($\text{log}_2\text{FC} = 1.84$) and `FGG` ($\text{log}_2\text{FC} = 1.76$).
*   **External Evidence:** COPD tissues exhibit tertiary lymphoid organs, B-cell expansion, and microvascular permeability.
*   **Next Step for Validation:** Perform single-cell RNA-sequencing (scRNA-seq) or spatial transcriptomics/multiplex immunohistochemistry on COPD vs control lung sections to map `FGG` and `IGKV1-8` expression to specific cell types.
*   **Conclusion Status:** **Exploratory hypothesis**

#### Priority 4: Cis-Regulatory Mechanism of LncRNAs `TGFB2-AS1` and `INHBA-AS1`
*   **Classification:** Interaction / network hypothesis
*   **Why Prioritize:** Antisense lncRNAs represent a major portion of top hits; understanding whether they activate or silence their parent coding genes (`TGFB2`, `INHBA`) is crucial for deciphering TGF-$\beta$ regulatory architecture.
*   **Current Dataset Evidence:** `TGFB2-AS1` ($\text{log}_2\text{FC} = 1.04$) and `INHBA-AS1` ($\text{log}_2\text{FC} = 1.19$) are significantly elevated.
*   **External Evidence:** Antisense RNAs can recruit chromatin modifying complexes or act as microRNA sponges to regulate parent gene transcription.
*   **Next Step for Validation:** Strand-specific RT-qPCR and Antisense Oligonucleotide (ASO) knockdown of `TGFB2-AS1` in human airway epithelial cells, followed by mRNA and protein quantification of `TGFB2`.
*   **Conclusion Status:** **Exploratory hypothesis**

#### Priority 5: ETV3L as a Novel Transcriptional Driver in COPD Airway Stress
*   **Classification:** Biomarker / Mechanistic hypothesis
*   **Why Prioritize:** `ETV3L` is the top overall statistically significant protein-coding DEG in the analysis ($\text{P} = 1.37 \times 10^{-15}, \text{FDR} = 2.75 \times 10^{-11}$).
*   **Current Dataset Evidence:** Strong, highly significant upregulation ($\text{log}_2\text{FC} = 1.47$).
*   **External Evidence:** ETV3L belongs to the PEA3 subfamily of ETS transcription factors, but its specific target genes and role in chronic pulmonary disease remain largely uncharacterized.
*   **Next Step for Validation:** CUT&RUN or ChIP-seq for ETV3L in damaged airway epithelial cells to map genome-wide binding sites and construct its core regulatory network.
*   **Conclusion Status:** **Exploratory hypothesis**

---

### 5. Evidence Grounding

```
Evidence Mapping & Triangulation
 ├── Direct Dataset Signals ──► High significance of ETV3L, RN7SK, MACF1, LncRNAs
 ├── Pathway Annotations ────► ECM Remodeling (GO:0045216), Coagulation (hsa04610)
 ├── Physical/PPI Evidence ──► MACF1 (Actin/MT), FGG (Fibrinogen), RN7SK (P-TEFb)
 └── Disease Literature ─────► GREM1 (Lung Fibrosis), DEFB1 (Mucosal Defense)
```

#### Supporting Evidence Evaluation
*   **Direct Dataset Evidence:** High statistical significance (FDR $< 0.05$) across multiple independent non-coding RNAs, cell-structuring components (`MACF1`), and immune/hemostatic elements (`FGG`, `DEFB1`).
*   **Pathway / Ontology Evidence:** Standardized enrichment points to cell-cell junction dynamics, complement and coagulation cascades, and RNA-mediated gene silencing.
*   **Protein Interaction Evidence:** Direct physical interaction evidence supports modules involving `MACF1` (cytoskeleton linker), `FGG` (fibrinogen chain assembly), `RN7SK` (P-TEFb sequestration), and `NACA2` (nascent peptide complex).
*   **Disease-Association Evidence:** `GREM1` and `DEFB1` have well-documented roles in pulmonary remodeling and airway mucosal defense in respiratory literature.

#### Overlapping vs. Independent Evidence Sources
*   *Overlapping:* The signals for `TGFB2-AS1`, `INHBA-AS1`, and `GREM1` derive from shared biological pathways (TGF-$\beta$ / BMP signaling cascade in tissue remodeling), representing convergent validation of a single macro-biological program.
*   *Independent:* The structural cytoskeletal program (`MACF1`), transcriptional pause machinery (`RN7SK`), and mucosal defensin defense (`DEFB1`) represent genuinely independent cellular mechanisms operating simultaneously in diseased lung tissue.

#### Conflicting and Insufficient Evidence
*   **Conflicting Evidence:** `DEFB1` is reported in some chronic smoking literature as being downregulated due to epithelial toxicity. In this dataset, `DEFB1` is upregulated ($\text{log}_2\text{FC} = 1.40$), which may reflect differences in patient exacerbation status, active infection, or tissue sampling site (parenchyma vs small airways).
*   **Insufficient Evidence:** Functional annotation for novel lncRNAs and pseudogenes (e.g., `SNX29-AS3`, `LOC100131395`, `RPL23AP32`) is insufficient to establish direct mechanistic causation; these must currently be classified as speculative/exploratory targets.

---

### 6. Limitations and Alternative Explanations

1.  **Tissue Heterogeneity and Cell-Composition Shifts:** Bulk lung tissue homogenates contain structural cells (epithelial, endothelial, fibroblasts) and resident/infiltrating immune cells (macrophages, lymphocytes, plasma cells). Upregulation of `IGKV1-8` or `FGG` likely reflects an increased proportion of infiltrating plasma cells or extravasated blood elements rather than transcriptional induction within parenchymal lung cells.
    *   *How to resolve:* Perform single-cell RNA sequencing (scRNA-seq) or immunohistochemical cell-type counting to deconvolve cell-type proportions from cell-intrinsic transcriptional changes.
2.  **Confounding by Active Smoking Status and Exacerbation History:** COPD cohorts often suffer from unmeasured clinical confounders, such as active cigarette smoking versus ex-smoker status, recent acute exacerbations, or corticosteroid therapy. Antimicrobial upregulation (`DEFB1`) may reflect acute microbial colonization rather than stable COPD pathology.
    *   *How to resolve:* Perform subgroup analysis stratifying patients by smoking pack-years, active smoking status, GOLD severity stage, and recent exacerbation events.
3.  **Mapping Ambiguity and Alignment Artifacts for Non-Coding/Pseudogene Transcripts:** A substantial portion of DEGs consists of antisense RNAs, pseudogenes (`UQCRBP1`, `RPL23AP32`), and uncharacterized `LOC` genes. Sequence homology can lead to read misassignment in short-read RNA sequencing.
    *   *How to resolve:* Validate non-coding hits using strand-specific RT-qPCR and long-read RNA sequencing (e.g., PacBio/Nanopore Iso-Seq).
4.  **Functional Ambiguity of Antisense Transcripts:** Upregulation of antisense lncRNAs (`TGFB2-AS1`, `INHBA-AS1`, `CELF2-AS1`) does not inherently indicate whether the functional outcome is upregulation, silencing, or spatial re-localization of the corresponding sense mRNA/protein.
    *   *How to resolve:* Perform strand-specific co-expression profiling and targeted ASO perturbation screens to observe direct effects on sense transcripts.
5.  **Association vs. Causation Ambiguity:** Differentially expressed structural markers (`MACF1`, `CLDN16`) may represent secondary protective or adaptive responses to chronic inflammation and tissue destruction rather than primary pathogenic drivers of COPD progression.
    *   *How to resolve:* Employ longitudinal animal models (e.g., chronic smoke exposure models) or genetic perturb-seq screens to determine temporal order and causality.
